Is Emideltide (DSIP) legal in the US?

By The Docket DeskResearched & sourcedUpdated 24 Jul 2026

The short answer

No — Emideltide is not an FDA-approved drug, and it is not currently legal to compound either. In April 2026 the FDA removed it from Category 2 (because the nominations were withdrawn), but did not move it to the approved Category 1 list, leaving it in a regulatory gray zone. On July 24, 2026 the committee voted against recommending it.

FDA approvalNot approved

Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized

PCAC recommendationRecommended against (Jul 24, 2026) — advisory; FDA makes the final call

Use under reviewOpioid withdrawal, chronic insomnia, and narcolepsy

Earliest pharmacy accessNo pathway open unless the FDA departs from the committee’s advice

Approved vs compoundable vs “research-use” — the distinction that matters

An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 Emideltide was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.

What happened on July 24

The FDA’s Pharmacy Compounding Advisory Committee heard the evidence and voted against adding Emideltide to the 503A list for insomnia — the only one of the seven substances the committee declined to recommend. The FDA is not bound by that vote, but it has opened no rulemaking here, and the current status is unchanged: off Category 2, not on Category 1, and not authorized for compounding.

Will Emideltide become legal in 2026?+

Not automatically. The committee voted against recommending it on July 24, 2026. The FDA still makes the final call, but it has opened no rulemaking here. Unless the FDA departs from the committee’s advice, no compounding pathway opens.

Is “research-grade” Emideltide the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: FDA 503A interim list; FDA-reviewed uses per PCAC agenda · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. Emideltide is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.